tbuckley/cabot-search huggingface dataset:
Assessment of Genetic Aberrations in Plasma Cells Using a Sequential Morphology (Phenotype)/FISH (Genotype) Approach Significantly Improves the Detection of Residual Disease in Post Treatment Multiple Myeloma.
Authors: Marilyn L. Slovak, Victoria Bedell, Kristen Pagel, Lawrence Weiss, David Smith, Yun Yen, Carol C. Shum, Daniel A. Arber, George Somlo
Journal: Blood (2005)
Rearrangement and Deletion of the PAX5 Gene in Pediatric Acute B-Cell Lineage Lymphoblastic Leukemia.
Authors: Norihiko Kawamata, Seishi Ogawa, Martin Zimmermann, Masashi Sanada, Kari Hemminki, Go Yamatomo, Yasuhito Nannya, Rolf Koehler, Thomas Flohr, Carl W. Miller, Jochen Harbott, Wolf-Dieter Ludwig, Martin Stanulla, Martin Schrappe, Claus R. Bartram, Phillip H. Koeffler
Journal: Blood (2007)
Prognostic Value of TREC, IL-7 and SCF Levels on Clinical Outcomes after Double Umbilical Cord Blood Transplantation in Adults
Authors: Ioannis Politikos, Haesook T. Kim, Sarah Nikiforow, Lequn Li, Karen K. Ballen, Joseph H. Antin, Jerome Ritz, Corey S Cutler, Vassiliki A. Boussiotis
Journal: Blood (2014)
A randomized multicenter study evaluating Xolair persistence of response after long-term therapy
Authors: Dennis Ledford, William Busse, Benjamin Trzaskoma, Theodore A. Omachi, Karin Rosén, Bradley E. Chipps, Allan T. Luskin, Paul G. Solari
Journal: Journal of Allergy and Clinical Immunology (2016)

BackgroundFew data are available to assist clinicians with decisions regarding long-term use of asthma therapies, including omalizumab.ObjectiveWe sought to evaluate the benefit and persistence of response in subjects continuing or withdrawing from long-term omalizumab treatment.MethodsEvaluating the Xolair Persistency Of Response After Long-Term Therapy (XPORT) was a randomized, double-blind, placebo-controlled withdrawal study that included subjects with moderate-to-severe persistent asthma receiving long-term omalizumab. Subjects were randomized by using a hierarchical dynamic randomization scheme to continue their same dose of omalizumab or withdraw to placebo and were then followed every 4 weeks for 1 year. The primary outcome was any protocol-defined severe asthma exacerbation. The secondary outcome was time to first protocol-defined severe asthma exacerbation. Exploratory outcomes included changes in Asthma Control Questionnaire and Asthma Control Test scores.ResultsSignificantly more subjects in the omalizumab group (67%) had no protocol-defined exacerbation than in the placebo group (47.7%); an absolute difference of 19.3% (95% CI, 5.0%, 33.6%) represents a 40.1% relative difference. Time to first protocol-defined exacerbation analysis revealed a significantly different between-group exacerbation pattern that was consistent with the primary analysis. Subjects continuing omalizumab had significantly better asthma control (mean [SD] change from baseline to week 52: Asthma Control Test score, −1.16 [4.14] vs placebo, −2.88 [5.38], P = .0188; Asthma Control Questionnaire score, 0.22 [0.66] vs placebo, 0.63 [1.13], P = .0039). Discontinuation of omalizumab was associated with an increase in free IgE levels and an increase in basophil expression of the high-affinity IgE receptor. No safety concerns were noted.ConclusionContinuation of omalizumab after long-term treatment results in continued benefit, as evidenced by improved symptom control and reduced exacerbation risk.
Survival Advantage with Hypomethylating Agents In Patients with Higher Risk Myelodysplastic Syndrome
Authors: Young-Hoon Park, Je-Hwan Lee, Kyoo Hyung Lee, Jung-Hee Lee, Dae-Young Kim, Sung-Doo Kim, Sung-Nam Lim, Yunsuk Choi, Miee Seol, Young-Shin Lee, Young-A Kang, Mijin Jeon
Journal: Blood (2010)
Waldeyer's Ring Marginal Zone B-Cell Lymphoma: Which Is Their Clinical and Prognostic Feature, Nodal or Extranodal?
Authors: Sung Yong Oh, Won Seog Kim, Jin Seok Kim, Seok Jin Kim, Suee Lee, Cheolwon Suh, Dae Ho Lee, Soon il Lee, Hye Jin Kang, Chul Won Choi, Seong Hyun Jeong, Jinny Park, Moo-Kon Song, Hyo Jung Kim, Jung Hye Kwon, Jae-Yong Kwak, Sung Hwa Bae, Byeong-Bae Park
Journal: Blood (2010)
Ocular Adnexal Marginal Zone B Cell Lymphoma Has Characteristic Deletion at Chromosome Band 6q23.3-24.1 Whose Target Is TNFAIP3.
Authors: Keiichiro Honma, Shinobu Tsuzuki, Masao Nakagawa, Sivasundaram Karnan, Won-Seog Kim, Yoon-Duk Kim, Young-Hyeh Ko, Masao Seto
Journal: Blood (2007)
NHS England is criticised for lack of transparency on service closures
Authors: Gareth Iacobucci
Journal: BMJ (2016)

NHS England is facing growing criticism over its stewardship of the 44 sustainability and transformation plans (STPs) that are proposing service closures and other changes to health and social care services across the country.

Local representatives from the NHS and local authorities have been drawing up plans since December 2015, when NHS England set them a deadline of 21 October 2016 to submit draft proposals to meet the triple aim of improving health, improving care, and saving money.

Friction has emerged since this deadline after four local councils opted to publish their local plans in draft form before they had been approved by NHS England and the regulator NHS Improvement, as they were concerned about the lack of transparency in the process.

The heat on NHS England intensified after a survey of clinical commissioning groups by the Health …
QOL-17IMPROVING THE CARE OF THE CAREGIVER: FINE TUNING A NEURO ONCOLOGY CAREGIVER PROGRAM
Authors: Margaretta Page, Idonah Molina, Judy Patt Smoker, Susan Chang
Journal: Neuro-Oncology (2015)

BACKGROUND: It is well documented that caregivers (CG) of neuro oncology patients have multiple needs across the disease trajectory. In September of 2013, the UCSF Neuro Oncology Program launched a service to proactively address the needs of the CG. The intent was to provide disease specific information, improve access to disease specific resources, and establish connections with others CGs in similar situations across the disease trajectory. We report on the expressed needs of 209 CGs and identified areas to fine tune the program. METHODS: CG outreach allowed for needs to be assessed across various domains. Following an analysis of the timing and nature of these expressed needs, we identified strategies and interventions to address these needs. RESULTS: CGs are particularly stressed in the post-operative period following diagnosis, prior to the first Neuro-Oncology appointment. We plan to launch an in-patient program to meet with CGs early on in the disease trajectory to provide education about the nature of the disease, introduce the CG team members and elaborate on expectations for care of the patient. CGs are clamoring for information and resources about topics that included how to prepare and tell their children about the parent's brain tumor, what to expect as the disease progresses and end of life care. CGs expressed feelings of isolation and the lack of a formal bereavement service. To specifically address these needs we have developed rich parenting resources; created 2 new educational manuals on progressive disease and end of life; formalized the outreach at the time of hospice referral and in the bereavement phase; improved awareness of support groups and the creation of caregiver specific support. CONCLUSIONS: Through the identification of CG needs we have implemented resources and services geared to enhance the support and QOL of the CG and the patient.
Antibody Targeting GRP78 Enhances the Efficacy of Radiation Therapy in Human Glioblastoma and Non–Small Cell Lung Cancer Cell Lines and Tumor Models
Authors: David Y.A. Dadey, Vaishali Kapoor, Kelly Hoye, Arpine Khudanyan, Andrea Collins, Dinesh Thotala, Dennis E. Hallahan
Journal: Clinical Cancer Research (2016)

Purpose: Non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM) have poor median survival. NSCLC and GBM overexpress glucose regulated protein 78 (GRP78), which has a role in radioresistance and recurrence. In this study, we determined the effect of anti-GRP78 antibody and the combined effect of the anti-GRP78 antibody with ionizing radiation (XRT) on NSCLC and GBM cell lines both in vitro and in vivoExperimental Design: NSCLC and GBM cancer cell lines were treated with anti-GRP78 antibodies and evaluated for proliferation, colony formation, cell death, and PI3K/Akt/mTOR signaling. The efficacy of anti-GRP78 antibodies on tumor growth in combination with XRT was determined in vivo in mouse xenograft models.Results: GBM and NSCLC cells treated with anti-GRP78 antibodies showed attenuated cell proliferation, colony formation, and enhanced apoptosis. GBM and NSCLC cells treated with anti-GRP78 antibodies also showed global suppression of PI3K/Akt/mTOR signaling. Combining antibody with XRT resulted in significant tumor growth delay in both NSCLC and GBM heterotopic tumor models.Conclusions: Antibodies targeting GRP78 exhibited antitumor activity and enhanced the efficacy of radiation in NSCLC and GBM both in vitro and in vivo GRP78 is a promising novel target, and anti-GRP78 antibodies could be used as an effective cancer therapy alone or in combination with XRT. Clin Cancer Res; 23(10); 2556-64. ©2016 AACR.
KLF4 Regulates Self-Renewal of Leukemic Stem Cells in Chronic Myeloid Leukemia By Repressing Gbl Expression and Altering mTORC2 Activity
Authors: Chun Shik Park, Ye Shen, Takeshi Yamada, Koramit Suppipat, Monica Puppi, Daniel Lacorazza
Journal: Blood (2014)
Guidelines for Listing Candidates for Heart Transplant
Authors: Mandeep R. Mehra
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapy
Authors: Jennifer A. Flemming, W. Ray Kim, Carol L. Brosgart, Norah A. Terrault
Journal: Hepatology (2016)

Direct‐acting antiviral (DAA) therapy, recently approved for patients with decompensated cirrhosis (DC) secondary to hepatitis C virus (HCV), is associated with improved hepatic function. We analyzed trends in liver transplant (LT) wait‐listing (WL) to explore potential impact of effective medical therapy on WL registration. This is a cohort study using the Scientific Registry of Transplant Recipients database from 2003 to 2015. A total of 47,591 adults wait‐listed for LT from HCV, hepatitis B virus (HBV), and nonalcoholic steatohepatitis (NASH) were identified. LT indication was defined as DC if the Model for End‐Stage Liver Disease (MELD) at WL was ≥15 or hepatocellular carcinoma (HCC). Era of listing was divided into interferon (IFN; 2003‐2010), protease inhibitor (PI; 2011‐2013), and direct‐acting antiviral (DAA; 2014‐2015). Annual standardized incidence rates of WL were analyzed using Poisson regression. Adjusted incidences of LT WL for DC in HCV patients decreased by 5% in the PI era ( P = 0.004) and 32% in the DAA era ( P &lt; 0.001) compared to the IFN era. Listing for DC in HBV also decreased in the PI (–17%; P = 0.002) and DAA eras (–24%; P &lt; 0.001). Conversely, WL for DC in NASH increased by 41% in the PI era ( P &lt; 0.001) and 81% in the DAA era ( P &lt; 0.001). WL for HCC in both the HCV and NASH populations increased in both the PI and DAA eras ( P &lt; 0.001 for all) whereas HCC WL in HBV remained stable ( P &gt; 0.05 for all). Conclusion : The rate of LT WL for HCV complicated by DC has decreased by over 30% in the era of DAA therapy. Further reductions in WL are anticipated with increased testing, linkage to care, and access to DAA therapy. (H epatology 2017;65:804‐812).
Phase II Study of Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) As First Salvage Therapy in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT): Final Results From the AZARELA-Trial (NCT-00795548)
Authors: Thomas Schroeder, Akos Czibere, Nicolaus Kröger, Uwe Platzbecker, Gesine Bug, Lutz Uharek, Thomas Luft, Christine Wolschke, Ingmar Bruns, Fabian Zohren, Roland Fenk, Rainer Haas, Guido Kobbe
Journal: Blood (2011)
Prevention of chemotherapy-induced alopecia in patients with breast or female genital tract cancer using sensor-controlled scalp-cooling
Authors: C.M. Kurbacher, S. Herz, G. Kolberg, N. Kettelhoit, A.T. Kurbacher, C. Schweitzer, K. Monreal, J.A. Kurbacher
Journal: Annals of Oncology (2016)
Transepidermal water loss in infancy associated with atopic eczema at 2 years of age: a population‐based cohort study
Authors: T.L. Berents, K.C. Lødrup Carlsen, P. Mowinckel, H.O. Skjerven, L.B. Rolfsjord, M. Bradley, K.‐H. Carlsen, P. Gjersvik
Journal: British Journal of Dermatology (2016)
FRI0526 Long-Term Efficacy of IL-1 Blockers in Papa Patients: Table 1
Authors: M. Finetti, R. Caorsi, D. Marotto, A. Buoncompagni, A. Omenetti, B. Lattanzi, F. Minoia, P. Picco, M. Jorini, A. Martini, M. Gattorno
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> PAPA syndrome (Pyogenic Arthritis, Pyoderma gangrenosum, and Acne) is an ultra-rare autosomal dominant, auto-inflammatory disease associated to mutations in the <i>PSTPIP1</i>/<i>CD2BP1</i> gene. The therapeutic approach during recurrences consists of steroids, while no agreement exists on the chronic management. Evidences on the use of biologics are anecdotal and variable results have been reported. <h3>Objectives</h3> To evaluate the long-term response to treatment with IL1 antagonist in six patients affected by PAPA syndrome. <h3>Methods</h3> Six patients (M:F=3:3; 4 pediatric, 1 young adult and 1 adult, mean age 18 years, range 3-50) affected by PAPA syndrome were enrolled and treated with IL1 blockers (5 patients Anakinra, 1 patient Anakinra followed by Canakinumab). Three patients were already treated with anti-TNFα monoclonal antibodies without benefit. Data were collected retrospectively (mean follow-up 26 months, range 4-38). The frequency of articular and cutaneous flares in the 24 months before starting therapy where compared to those occurred during anti-IL1 regimen. Acute phase reactants (ESR, CRP, SAA) were assessed at the last visit before the study enrolment and at last follow-up. <h3>Results</h3> All the patients displayed a significant decrease in frequency of disease flares (Table) and normalization of acute phase reactants. Three patients were asymptomatic during whole follow-up. Patient#4, with a severe and persistent pyoderma gangrenosum, displayed a partial response to Anakinra partially due to a poor compliance to daily s.c. administration. The shift to Canakinumab lead to a fast and complete resolution of the skin manifestations. <h3>Conclusions</h3> The long-term use of IL1 blockers is associated to satisfactory and persistent control of clinical manifestations and laboratory findings in PAPA syndrome. <h3>Disclosure of Interest</h3> M. Finetti: None declared, R. Caorsi: None declared, D. Marotto: None declared, A. Buoncompagni: None declared, A. Omenetti: None declared, B. Lattanzi: None declared, F. Minoia: None declared, P. Picco: None declared, M. Jorini: None declared, A. Martini Grant/research support from: Unrestricted grants from SOBI and Novartis, Speakers bureau: Speaker9s fees, M. Gattorno Grant/research support from: Unrestricted grants from SOBI and Novartis, Speakers bureau: Speaker9s fees
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
Authors: Matthew E. Kennedy, Andrew W. Stamford, Xia Chen, Kathleen Cox, Jared N. Cumming, Marissa F. Dockendorf, Michael Egan, Larry Ereshefsky, Robert A. Hodgson, Lynn A. Hyde, Stanford Jhee, Huub J. Kleijn, Reshma Kuvelkar, Wei Li, Britta A. Mattson, Hong Mei, John Palcza, Jack D. Scott, Michael Tanen, Matthew D. Troyer, Jack L. Tseng, Julie A. Stone, Eric M. Parker, Mark S. Forman
Journal: Science Translational Medicine (2016)

β-Amyloid (Aβ) peptides are thought to be critically involved in the etiology of Alzheimer's disease (AD). The aspartyl protease β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is required for the production of Aβ, and BACE1 inhibition is thus an attractive target for the treatment of AD. We show that verubecestat (MK-8931) is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of Aβ40, Aβ42, and sAPPβ (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys. Chronic treatment of rats and monkeys with verubecestat achieved exposures >40-fold higher than those being tested in clinical trials in AD patients yet did not elicit many of the adverse effects previously attributed to BACE inhibition, such as reduced nerve myelination, neurodegeneration, altered glucose homeostasis, or hepatotoxicity. Fur hypopigmentation was observed in rabbits and mice but not in monkeys. Single and multiple doses were generally well tolerated and produced reductions in Aβ40, Aβ42, and sAPPβ in the CSF of both healthy human subjects and AD patients. The human data were fit to an amyloid pathway model that provided insight into the Aβ pools affected by BACE1 inhibition and guided the choice of doses for subsequent clinical trials.
Mycophenolate Compared to Methotrexate As Part of Cyclosporine Based-GVHD Prophylaxis Does Not Affect Transplant Outcomes, Reduces Organ Specific Acute And Chronic GVHD, but Increases The Risk of CMV Viremia In Matched Related Donor Peripheral Blood Stem Cell Transplantation
Authors: Nada Hamad, Mohamed Shanavas, Fotios V. Michelis, Jieun Uhm, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner, Dennis Kim
Journal: Blood (2013)
Validation of PROMIS emotional distress short form scales for cervical cancer trials.
Authors: Lari B. Wenzel, Kathryn Osann, Susie Hsieh, Edward L. Nelson, David Cella
Journal: Journal of Clinical Oncology (2013)

6633 Background: PROMIS is an NIH-sponsored effort to standardize the measurement of common symptoms and functional concerns of people with chronic conditions. The purpose of this study is to validate the PROMIS Emotional Distress (Depression and Anxiety) Short Forms (SFs) for use with cervical cancer patients. Methods: In a randomized psychosocial telephone counseling (PTC) trial, PROMIS measures of depression and anxiety were used alongside more traditional “legacy” measures of the same concepts. Questionnaires were administered to patients prior to randomization, four months post enrollment, and nine months post enrollment. The depression (8-item) and anxiety (7-item) SFs were evaluated in patients participating in this study, for internal consistency, concurrent validity, and responsiveness to change. SF performance results were compared to the Brief Symptom Inventory (BSI-18) subscales. Data were collapsed between PTC and usual care treatment arms for these analyses. Results: Patients showed significant improvement in depression from baseline to 4 months post study enrollment as measured by the Depression SF (p=0.003; effect size = 0.24), and BSI-Dep (p=0.041; effect size = 0.25). Internal consistency of the two PROMIS SFs were ≥0.95 at baseline (N=203), 4 months (N=165), and 9 months (N=151). The average inter-item correlation was 0.71 at the 4 month assessment for both depression and anxiety. The Depression SF T-score correlated well with the BSI-Dep (0.74), and was moderately correlated with the FACT Emotional Well-Being (EWB) subscale (-0.54), and the Perceived Stress Scale (PSS)(0.63). The Anxiety SF T-score was moderately correlated with BSI-Anx (0.60), EWB (-0.53), and PSS (0.60). Conclusions: The PROMIS Depression and Anxiety SFs reliably and validly assess cervical cancer-specific emotional distress, they capture salient features of distress in this population, and they perform as well or better than legacy measures in this gynecologic cancer population. Clinical trial information: NCT00496106.
Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults
Authors: Nancy J. Donovan, Olivia I. Okereke, Patrizia Vannini, Rebecca E. Amariglio, Dorene M. Rentz, Gad A. Marshall, Keith A. Johnson, Reisa A. Sperling
Journal: JAMA Psychiatry (2016)

Emotional and behavioral symptoms in cognitively normal older people may be direct manifestations of Alzheimer disease (AD) pathophysiology at the preclinical stage, prior to the onset of mild cognitive impairment. Loneliness is a perceived state of social and emotional isolation that has been associated with cognitive and functional decline and an increased risk of incident AD dementia. We hypothesized that loneliness might occur in association with elevated cortical amyloid burden, an in vivo research biomarker of AD.To determine whether cortical amyloid burden is associated with greater loneliness in cognitively normal older adults.Cross-sectional analyses using data from the Harvard Aging Brain Study of 79 cognitively normal, community-dwelling participants. A continuous, aggregate measure of cortical amyloid burden, determined by Pittsburgh Compound B-positron emission tomography (PiB-PET), was examined in association with loneliness in linear regression models adjusting for age, sex, apolipoprotein E ε4 (APOEε4), socioeconomic status, depression, anxiety, and social network (without and with the interaction of amyloid and APOEε4). We also quantified the association of high amyloid burden (amyloid-positive group) to loneliness (lonely group) using logistic regression, controlling for the same covariates, with the amyloid-positive group and the lonely group, each composing 32% of the sample (n = 25).Loneliness, as determined by the 3-item UCLA Loneliness Scale (possible range, 3-12, with higher score indicating greater loneliness).The 79 participants included 43 women and 36 men with a mean (SD) age of 76.4 (6.2) years. Mean (SD) cortical amyloid burden via PiB-PET was 1.230 (0.209), and the mean (SD) UCLA-3 loneliness score was 5.3 (1.8). Twenty-two (28%) had positive APOEε4 carrier status, and 25 (32%) were in the amyloid-positive group with cortical PiB distribution volume ratio greater than 1.2. Controlling for age, sex, APOEε4, socioeconomic status, depression, anxiety, and social network, we found that higher amyloid burden was significantly associated with greater loneliness: compared with individuals in the amyloid-negative group, those in the amyloid-positive group were 7.5-fold (95% CI, 1.7-fold to 34.0-fold) more likely to be classified as lonely than nonlonely (β = 3.3, partial r = 0.4, P = .002). Furthermore, the association of high amyloid burden and loneliness was stronger in APOEε4 carriers than in noncarriers.We report a novel association of loneliness with cortical amyloid burden in cognitively normal older adults, suggesting that loneliness is a neuropsychiatric symptom relevant to preclinical AD. This work will inform new research into the neural underpinnings and disease mechanisms involved in loneliness and may enhance early detection and intervention research in AD.